GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Q2 FY27 Net Profit at Rs. 517.18 Million, Revenue Rs. 2,799.28 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Nov 2026, 07:47 PM IST  ·  BSE ID: 02783d27-c981-430d-b375-2a8a50ac6467
View Original BSE Filing (PDF)
💡
In Simple Terms
Symbiotec Pharmalab released its latest financial results, showing earnings and sales for the recent quarter and half-year.
🤖 AI Summary
  • Symbiotec Pharmalab reported Q2 FY27 unaudited consolidated Net Profit of Rs. 517.18 Million.
  • Q2 FY27 Revenue from operations was Rs. 2,799.28 Million; total income reached Rs. 2,800.40 Million.
  • Half-year ended September 30, 2026, Revenue from operations totaled Rs. 4,980.78 Million.
  • Net Profit for the half-year ended September 30, 2026, stood at Rs. 657.79 Million.
  • Company completed IPO on September 1, 2026, increasing paid-up equity share capital to Rs. 128.51 Million.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
2,799.28 Million
43.19
Net Profit for the period (Q2 FY27)
517.18 Million
169.13
Revenue from operations (Half-year ended Sep 30, 2026)
4,980.78 Million
24.93
Net Profit for the period (Half-year ended Sep 30, 2026)
657.79 Million
33.86
Paid-up equity share capital (As at Sep 30, 2026)
128.51 Million
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations to Rs. 2,799.28 Million for Q2 FY27 indicates continued business activity for Symbiotec Pharmalab.
💰
Financial Impact
Net Profit of Rs. 517.18 Million for Q2 FY27 contributes to the company's earnings. Paid-up equity share capital increased to Rs. 128.51 Million following the IPO.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Existing shareholders are affected by the company's financial performance, specifically the Q2 FY27 Net Profit of Rs. 517.18 Million and revenue growth. New shareholders from the recent IPO are also affected.
🔍
Management Signal
The approval of unaudited financial results and the recent completion of the IPO signal management's focus on operational performance and financial reporting compliance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — monitor sustainability of revenue growth and profitability.
Details on IPO net proceeds utilization — assess deployment for stated objectives.
Future board meeting outcomes — observe any declarations or strategic announcements.
LOW RISK Financial results show growth with no explicit new risks mentioned.
💡 Investor Takeaway
Symbiotec Pharmalab reported Q2 FY27 consolidated Net Profit of Rs. 517.18 Million, with Revenue from operations at Rs. 2,799.28 Million. This reflects an increase in profitability and revenue compared to the prior year's comparable quarter. Half-year Net Profit reached Rs. 657.79 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Revenue from operations increased to Rs. 2,799.28 Million compared to Rs. 1,955.15 Million in Q2 FY26.
  • Half-year ended September 30, 2026, Net Profit rose to Rs. 657.79 Million from Rs. 491.38 Million in the prior half-year.

⚠️ Concerns

  • Total income tax expense for Q2 FY27 was Rs. 123.26 Million, compared to Rs. 142.52 Million in Q2 FY26.
  • Finance costs for the half-year ended September 30, 2026, increased to Rs. 118.83 Million from Rs. 116.63 Million.
📅 Company Track Record
Recently listed — IPO completed on September 1, 2026, with equity shares listed on NSE and BSE. The paid-up equity share capital increased from Rs. 125.47 Million to Rs. 128.51 Million due to the fresh issue of 1,521,261 equity shares.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Symbiotec Pharmalab's Net Profit for Q2 FY27?
Symbiotec Pharmalab reported an unaudited consolidated Net Profit of Rs. 517.18 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Symbiotec Pharmalab's Revenue from operations in Q2 FY27?
The Revenue from operations for Symbiotec Pharmalab in Q2 FY27 was Rs. 2,799.28 Million.
What is Symbiotec Pharmalab's Net Profit for the half-year ended September 30, 2026?
For the half-year ended September 30, 2026, Symbiotec Pharmalab's Net Profit stood at Rs. 657.79 Million.
When did Symbiotec Pharmalab complete its IPO and what was the impact on equity capital?
Symbiotec Pharmalab completed its Initial Public Offering on September 1, 2026. This increased the paid-up equity share capital from Rs. 125.47 Million to Rs. 128.51 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.